RIGL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Rigel Pharmaceuticals Inc (RIGL) is a good buy for a beginner investor with a long-term horizon and $50,000-$100,000 available for investment. The company has demonstrated strong financial growth in the latest quarter, with significant YoY increases in revenue, net income, and EPS. While technical indicators are mixed, the positive MACD and proximity to support levels suggest potential for upward movement. Options data reflects bullish sentiment with a low put-call ratio, and the lack of recent negative news or significant insider/hedge fund activity further supports the buy decision.
The MACD histogram is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 40.117, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near the pivot level of 26.126, with support at 25.243 and resistance at 27.008.
Strong financial performance in Q4 2025, with revenue up 21.19% YoY, net income up 1769.22% YoY, and EPS up 1557.50% YoY. Gross margin also increased to 91.47%.
Bearish moving averages and lack of recent news or event-driven catalysts. No recent significant insider or hedge fund activity.
In Q4 2025, Rigel Pharmaceuticals reported a 21.19% YoY increase in revenue to $69.8M, a 1769.22% YoY increase in net income to $268.07M, and a 1557.50% YoY increase in EPS to 13.26. Gross margin improved to 91.47%, up 1.69% YoY.
No recent analyst rating or price target changes available for analysis.
